Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68797 | 0.84 | ADRB2 (0.42) | ADRB2TSHRHIF1AADRA1ASLC22A1 | |
| SCHEMBL16984606 | 0.81 | ESR1 (0.50) | TSHRHIF1AADRA1AOPRM1LMNA | |
| SCHEMBL2952875 | 0.73 | ADRB2 (0.53) | ADRB2TSHRHIF1AADRA1ACYP3A4 | |
| SCHEMBL27679481 | 0.72 | LMNA (0.43) | ADRA1ALMNAKMT2AMEN1 | |
| SCHEMBL68774 | 0.72 | ADRB2 (0.54) | ADRB2TSHRHIF1AADRA1ACYP3A4 | |
| SCHEMBL27665518 | 0.72 | KYNU (0.49) | HIF1ALMNAKMT2ACYP3A4CYP2C9 | |
| SCHEMBL11831177 | 0.70 | ADRB2 (0.53) | ADRB2TSHRHIF1AADRA1ACYP3A4 | |
| SCHEMBL19333069 | 0.70 | ESR1 (0.33) | TSHRADRA1AOPRM1LMNACYP3A4 | |
| SCHEMBL11828601 | 0.70 | ADRB2 (0.53) | ADRB2TSHRHIF1AADRA1ACYP3A4 | |
| SCHEMBL2953489 | 0.70 | ADRB2 (0.53) | ADRB2TSHRHIF1AADRA1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479203-A1 | AROMATIC POLYESTER | Muroran Institute of Technology (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172570-A1 | AROMATIC POLYESTER | NITTA CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-8129493-B2 | Aromatic polyester | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110092662-A1 | AROMATIC POLYESTER | NITTA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-7759526-B2 | Pharmaceutical compositions comprising cannabidiol derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2010-07-20 | — | — | US | disclosed |
| EP-1289517-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIDIOL DERIVATIVES | YISSUM RES DEV CO (IL) | 2005-11-16 | — | — | EP | disclosed |
| US-20030166727-A1 | Pharmaceutical compositions comprising cannabidiol derivatives | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-09-04 | — | — | US | disclosed |
| EP-1289517-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIDIOL DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001095899-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CANNABIDIOL DERIVATIVES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-12-20 | — | — | WO | disclosed |
| US-4876276-A | ANALGESICS, ANTIEMETICS, AND ANTIGLAUCOMA AGENTS NO CANNABIMIMETIC EFFECTS | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-10-24 | — | — | US | disclosed |
| US-4179517-A | DEVOID OF \"CANNABIS-TYPE\" CENTRAL NERVOUS SYSTEM ACTIVITY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166727-A1 | Pharmaceutical compositions comprising cannabidiol derivatives | CNR2, CNR1, FAAH | ADRB2 764/4885TSHR 4623/4885HIF1A 2342/4885 |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | F12, PHAX, WDR82 | ADRB2 1430/4885TSHR 3263/4885HIF1A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.